CD274 and lymphoma: Although lymphocytes, macrophages and other immune cells have historically represented the basis that led to the development of modern ICI, anti-PD-L1 therapy has been less extensively studied in hematological neoplasms, especially lymphomas, than other solid malignancies [95].